Evidence map›Paper›PMID 25588744›Full record

ArticleGene therapy2015

Sendai virus-mediated gene transfer of the c-myc suppressor far-upstream element-binding protein-interacting repressor suppresses head and neck cancer.

N Tanaka, K Araki, D Mizokami, Y Miyagawa, T Yamashita, M Tomifuji, Y Ueda, M Inoue, K Matsushita, F Nomura and 2 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Gene therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. International journal of molecular sciences · 2026
    Review
  2. Review
  3. Review
  4. Viral and Synthetic RNA Vector Technologies and Applications.Molecular therapy : the journal of the American Society of Gene Therapy · 2016
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

N TanakaDepartment of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
K ArakiDepartment of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
D MizokamiDepartment of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
Y MiyagawaDepartment of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
T YamashitaDepartment of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
M TomifujiDepartment of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
Y UedaDepartment of Gene Medicine, DNAVEC Corporation, Ibaraki, Japan.
M InoueDepartment of Gene Medicine, DNAVEC Corporation, Ibaraki, Japan.
K MatsushitaDepartment of Molecular Diagnosis and Division of Clinical Genetics and Proteomics, Chiba University Graduate School of Medicine, Chiba, Japan.
F NomuraDepartment of Molecular Diagnosis and Division of Clinical Genetics and Proteomics, Chiba University Graduate School of Medicine, Chiba, Japan.
H ShimadaDepartment of Surgery, Toho University School of Medicine, Tokyo, Japan.ORCID 0000000219908217
A ShiotaniDepartment of Otorhinolaryngology - Head and Neck Surgery, National Defense Medical College, Saitama, Japan.
National Defense Medical College · JPChiba University · JPID Pharma (Japan) · JPToho University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Far-upstream element-binding protein-interacting repressor (FIR) is a transcription factor that inhibits c-Myc expression and has been shown to have antitumor effects in some malignancies. Here, we evaluated the antitumor effects of FIR using fusion gene-deleted Sendai virus (SeV/ΔF) as a nontransmissible vector against head and neck squamous cell carcinoma (HNSCC). Using in vitro and in vivo xenograft mouse models, we observed efficient expression of green fluorescent protein (GFP) following transduction with the SeV/ΔF vector encoding GFP (GFP-SeV/ΔF) into HNSCC cells. In vitro and in vivo studies revealed that administration of the FIR-encoded SeV/ΔF (FIR-SeV/ΔF) vector exerted significant antitumor effects, suppressed c-Myc expression and induced apoptosis in HNSCC. Additionally, the antitumor effects of FIR or the expression of GFP following administration of the FIR- or GFP-SeV/ΔF vector, respectively, were dependent on the multiplicity of infection or titer. Furthermore, the SeV/ΔF vector itself had no cytotoxic effects. Therefore, the SeV/ΔF vector may be safe and useful for the treatment of HNSCC, allowing for high-titer SeV/ΔF vector administration for anticancer gene therapy. In addition, SeV/ΔF vector-mediated FIR gene therapy demonstrated effective tumor suppression in HNSCC, suggesting that this therapy may have the potential for clinical use as a novel strategy for HNSCC treatment.

Indexed as

AnimalsCell LineFemaleGenetic TherapyGenetic VectorsGene Transfer TechniquesGuanine Nucleotide Exchange FactorsHead and Neck NeoplasmsHeterograftsHumansMiceNeoplasm TransplantationProto-Oncogene Proteins c-mycSendai virusFARP2 protein, humanGuanine Nucleotide Exchange FactorsMYC protein, humanProto-Oncogene Proteins c-myc

Identifiers

PMID25588744
OpenAlexW2078560625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.